KDM4B: A promising oncology therapeutic target

IF 4.5 2区医学 Q1 ONCOLOGY

Cancer Science Pub Date : 2023-11-03 DOI:10.1111/cas.16005

Fangjing Ni, Heting Tang, Siteng Cheng, Yaoyu Yu, Zhihao Yuan, Yingfei Chen, Encheng Zhang, Xiang Wang

{"title":"KDM4B: A promising oncology therapeutic target","authors":"Fangjing Ni, Heting Tang, Siteng Cheng, Yaoyu Yu, Zhihao Yuan, Yingfei Chen, Encheng Zhang, Xiang Wang","doi":"10.1111/cas.16005","DOIUrl":null,"url":null,"abstract":"<p>Epigenetic modifications are significant in tumor pathogenesis, wherein the process of histone demethylation is indispensable for regulating gene transcription, apoptosis, DNA replication, and repair of damaged DNA. The lysine demethylases (KDMs) serve an essential role in the aforementioned processes, with particular emphasis on the KDM4 family, also referred to as JMJD2. Multiple studies have underscored the significance of the KDM4 family in the regulation of various biological processes including, but not limited to, the cell cycle, DNA repair mechanisms, signaling pathways, and the progression of tumor formation. Nevertheless, it is imperative to elucidate the underlying mechanism of KDM4B, which belongs to the <i>KDM4</i> gene family. This review presents a comprehensive examination of the structure, mechanism, and function of KDM4B, as well as a critical analysis of the current body of research pertaining to its involvement in tumorigenesis and development. Furthermore, this review explores the potential therapeutic strategies that specifically target KDM4B.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 1","pages":"8-16"},"PeriodicalIF":4.5000,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823266/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Epigenetic modifications are significant in tumor pathogenesis, wherein the process of histone demethylation is indispensable for regulating gene transcription, apoptosis, DNA replication, and repair of damaged DNA. The lysine demethylases (KDMs) serve an essential role in the aforementioned processes, with particular emphasis on the KDM4 family, also referred to as JMJD2. Multiple studies have underscored the significance of the KDM4 family in the regulation of various biological processes including, but not limited to, the cell cycle, DNA repair mechanisms, signaling pathways, and the progression of tumor formation. Nevertheless, it is imperative to elucidate the underlying mechanism of KDM4B, which belongs to the KDM4 gene family. This review presents a comprehensive examination of the structure, mechanism, and function of KDM4B, as well as a critical analysis of the current body of research pertaining to its involvement in tumorigenesis and development. Furthermore, this review explores the potential therapeutic strategies that specifically target KDM4B.

Abstract Image

查看原文本刊更多论文

KDM4B：一个有前景的肿瘤治疗靶点。

表观遗传学修饰在肿瘤发病机制中具有重要意义，其中组蛋白去甲基化过程对于调节基因转录、细胞凋亡、DNA复制和损伤DNA的修复是必不可少的。赖氨酸去甲基酶（KDMs）在上述过程中发挥重要作用，特别强调KDM4家族，也称为JMJD2。多项研究强调了KDM4家族在调节各种生物过程中的重要性，包括但不限于细胞周期、DNA修复机制、信号通路和肿瘤形成的进展。然而，必须阐明属于KDM4基因家族的KDM4B的潜在机制。这篇综述对KDM4B的结构、机制和功能进行了全面的研究，并对其参与肿瘤发生和发展的现有研究进行了批判性分析。此外，本综述探讨了专门针对KDM4B的潜在治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.